StockUS listing USBEAMNASDAQHealthcareEarnings Deterioration

Beam Therapeutics Inc(BEAM) Stock Analysis | Healthcare

USD --+0.00%
Reward43Moderate
Risk72High
75%Data
Thin -74% profit margin · Revenue down 97% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 2.16Bn
Reward Ratingⓘ43 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ72 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BEAM to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Beam Therapeutics Inc?

, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

AI Brief Pro

The brief on Beam Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Beam Therapeutics Inc?

, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.16B.

Financial Highlights

Investment Breakdown

Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (43)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta2.219
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
350,187 shares
$1.2M
0
3-6months
8351,900 shares
$12.2M
0
6-9months
8142,786 shares
$3.7M
0
9-12months
12,906 shares
$84k
0